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Abstract 
Background: Diabetic foot ulcers (DFUs) are one of the most feared complications of Diabetes Mellitus (DM), 
which often become infected leading to complications like osteomyelitis, amputations and septicemia. There are 
scanty reports of data regarding the patterns and the cost analysis of antibacterial therapy to treat 
DFUs.Objectives: To study the prescribing pattern, approval status, inclusion in World Health Organization 
(WHO) essential medicines list/National List of Essential Medicines (NLEM) and rationality of antibacterials 
prescribed in the management of DFUs.Methods: Data was collected from records of 52 inpatients with a 
diagnosis of DFU from Saraswati Medical College, Unnao, U.P., India. The prescribing patterns, approval status, 
cost and listing of antibacterials in WHO essential medicines list/ NLEM were analysed. The data was presented 
as percentages, mean and standard deviations.Results: Among the 13 positive culture data, 10(77%) were gram 
negative in nature. Of the 155 antibacterial prescriptions analysed, single drug formulations were most commonly 
prescribed [109 (70.32%)]; 144 (92.90%) were approved by Drug Controller General of India (DCGI) and 135 
(87.10%) by United States Food and Drug Administration (USFDA); 101 (65.16%) antibacterials were included 
in both WHO and NLEM; parenteral formulations were the commonly used dosage forms [97 (62.58%)]. The 
most common class of antibacterials prescribed were beta-lactams [Anatomical Therapeutic Chemical (ATC) 
class: J01C and J01D], both before and after culture and sensitivity (C/S) testing [79(63.2%) and 15(50%) 
respectively]. Only 16 (10.32%) drugs were prescribed by their generic names. The average cost per dose and the 
total cost during hospital stay for quinolones were Rs. 7.24, Rs. 92.95 and Rs. 416.97, Rs. 5539.06 for β-Lactams 
respectively.Conclusion: Gram negative organisms were most commonly isolated. Parenteral formulations were 
preferred over oral formulations and single drug formulations over fixed dose combinations (FDCS) in the 
management of DFUs. Beta-lactams comprised the major class of antibacterials prescribed before and after C/S 
testing. More than 80% of the antibacterials prescribed were approved by DCGI and USFDA and almost 60% 
were included in the WHO essential medicines list and NLEM. The average cost per dose and the total cost 
during hospital stay were highest for β-lactam antibacterials and least for quinolones. 
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Introduction  
 
Diabetes mellitus (DM) represents a group of 
metabolic diseases characterized by hyperglycemia  
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resulting either from defects in insulin secretion, 
insulin action, or both[1].Around 347 million people 
worldwide have diabetes. Type 2 DM accounts for 
around 90% of all diabetics worldwide[2]. India has 
around 50.8 million diabetic patients at  present and 
the figures may double by 2025[3]. DM is predicted 
to become the seventh leading cause of death in the 
world by the year 2030. Deaths from diabetes related 
complications are projected to rise by more than 50% 
in the next 10 years. In developed countries most 
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people with DM are above the age of retirement, 
whereas in developing countries those most 
frequently affected are aged between 35 and 64[2]. 
DM is the leading cause of end-stage renal disease 
(ESRD), nontraumatic lower extremity amputations, 
and adult blindness[2,4].The increasing incidence of 
DM has given rise to problem of chronic diabetic 
ulcers[5]. Diabetic foot ulcer (DFU) is one of the 
dreadful complications of DM and is the leading 
cause of hospitalization among diabetic patients[6]. 
Approximately 15 to 20% of DM patients have foot 
problems and 10 to 15% of all hospital admissions 
are due to major foot infections. 50% of all non-
traumatic major amputations are due to DM related 
complications. Around 85% of diabetic foot 
amputations are due to inadequate and late treatment 
of diabetic foot ulcers and infections. The lifetime 
incidence of foot ulcers may be as high as 25%.3 
Peripheral neuropathy, peripheral vascular disease 
and infection which are among the long term 
complications of DM contribute to the multifactorial 
pathogenesis of DFUs[5]. These ulcers frequently 
become infected, cause great morbidity, give rise to 
considerable financial burden and may end up in 
lower extremity amputations[7].Recognizing and 
treating foot problems early can help diabetic patients 
avoid serious complications[3].Foot infections in 
diabetic patients are initially treated empirically. 
Hence, while selecting antibacterials, one should 
consider severity of infection, route of drug 
administration, co-morbidities and spectrum of 
organisms to be covered. Therapy directed at known 
causative organisms can significantly improve the 
outcome and reduce infection related morbidity and 
mortality. In India, the choice of empirical 
antibacterials is extrapolated from data available 
from western countries, which may or may not be 
appropriate for Indian patients[8]. The increasing 
association of multi-drug resistant (MDR) pathogens 
with DFUs further challenges the physician or the 
surgeon in treating diabetic ulcers without resorting 
to amputation[6].The principal aim of drug utilization 
research is to facilitate the rational use of drugs in 
populations i.e., the prescription of a well 
documented drug at an optimal dose, together with 
the correct information, at an affordable price. 
Information on the past performance of prescribers is 
vital for any auditing system. A precise knowledge of 
how drugs are being prescribed and used is essential 
to initiate a discussion on rational drug use or to 
suggest measures to improve prescribing habits. Drug 
utilization research in itself does not necessarily 
provide answers, but it contributes to rational drug 
use in important ways[9].Keeping the above things in 
mind, the present study was taken up to evaluate the 
prescribing patterns of antibacterials used in the 
management of DFUs. 
Materials and methods 
Study location: Saraswati Medical College, Unnao, 
U.P., India 
Study design: Cross-sectional study 
Data collection: The relevant data was collected 
from records of 52 inpatients with a diagnosis of 
diabetic foot ulcer admitted during Saraswati 
Medical College, Unnao, U.P., India. The study was 
initiated after approval from the institutional human 
ethics committee. 
To evaluate the drug prescribing pattern, a proforma 
containing relevant details such as demographics 
(age, sex), inpatient number, admission and discharge 
dates, duration of hospital stay, clinical data (Clinical 
diagnosis and associated co-morbid conditions), 
surgical data (debridement, amputation, skin 
grafting), laboratory  parameters (hemoglobin %, 
FBS, PPBS, RBS, A1C%, blood urea, serum 
creatinine, urine routine, culture and sensitivity) were 
recorded. Antibacterials prescribed (generic/brand 
name) with respect to dosage, route, frequency and 
duration of administration, before and after culture 
sensitivity were recorded as per proforma. Drugs 
prescribed apart from antibacterials were also 
recorded in the same proforma. 
Inclusion criteria 
Age: 20-80 years 
Sex: Either sex 
Patients with a diagnosis of diabetic foot ulcer 
Exclusion criteria 
Pregnant and lactating women 
Ulcers in sites other than foot 
Diabetic patients with HIV and tuberculosis 
Diabetic patients on cancer chemotherapy, long term 
steroid use and other immunosuppressant drugs 
Analysis of data 
The data was subjected to descriptive analysis using 
Microsoft Excel version 2007. 
Utilization of different classes of drugs as well as 
individual drugs were analyzed and presented as 
percentage.Approval status of the drugs was checked 
in the official website for Central Drugs Standard 
Control Organization (CDSCO), Directorate General 
of Health Services, India[10] and Drugs@FDA: FDA 
Approved Drug Products [11].Whether the 
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prescribed antibacterials were listed in the WHO 
essential medicines list and National List of Essential 
Medicines was found out from the WHO Model List 
of essential medicines 2011 and NLEM India 
2011[12,13]. 
Drugs were classified into different groups based on 
WHO/ATC classification. 
ATC/DDD of each antibacterial prescribed was 
adopted from official website of WHO[14]. 
Daily defined dose (DDD) of each drug type was 
calculated as the total quantity of drug administered 
divided by the number of patient-days the drug was 
given[15]. 
Cost of individual drugs was calculated by taking 
into consideration the average cost of leading brands 
of drugs available. 
 
 
Results 
Demographic data 
 52 patients admitted with a diagnosis of DFU were 
included in the study. Out of 52 patients, 47(90%) were 
males and 5(10%) females (fig.4), with male to female 
ratio of 9.4:1.The mean age of males was 56.02 ± 11.95 
years and that of females 65.6 ± 15.19 years.Majority of 
the patients [16 (30.77%)] were in the age group 
between  51-60 years. The least affected were between 
71-80 years [7 (13.46%)], followed by 30-40 years [8 
(15.38%)]. 
Comorbid illness 
Out of 52 patients, 20(38%) had hypertension (HTN), 
3(6%) diabetic nephropathy, 2(4%) cerebrovascular 
accidents (CVA), 1(2%) ischemic heart disease (IHD) 
and 1(2%) osteomyelitis. The remaining 25(48%) did 
not have any co morbid illnesses. The mean duration of 
hospital stay was 22.81 ± 18.57 days.(Fig.1) 
Table 1: Surgical interventions 
Sl no Surgical interventions Numbers(n=52) Percentage 
1 Debridement as one of the surgical interventions 33 63.46 
2 Skin grafting as one of the surgical interventions 9 17.31 
3 Amputation as one of the surgical interventions 5 9.62 
4 Debridement as the only surgical intervention 22 42.31 
5 Skin grafting as the only surgical intervention 0 0 
6 Amputation as the only surgical intervention 2 3.85 
7 Debridement + skin grafting 9 17.31 
8 Debridement + amputation 2 3.85 
9 More than one surgical intervention 11 21.15 
 
Out of 52 patients, 33(63%) had undergone debridement, 9(17%) skin grafting and 5(9.6%) amputation; 
11(21.15%) had undergone more than one surgical intervention. (Table 1). 
Microbiological Data 
Table 2: Culture/sensitivity data 
 
Sl no Data Number Percentage 
1 C/S available 16/52 30.77 
2 Growth 13/16 81.25 
3 No growth 3/16 18.75 
 
Among 52 inpatient records, culture sensitivity data was available only for 16(30.77%) patients as shown in table 
2. 
Of the 16 inpatient records having culture sensitivity data, 13(81.25%) showed positive cultures.Of the 13 positive 
culture data, 3(23%) organisms were gram positive and 10(77%) were gram negative in nature as shown in Fig.2 
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Table 3: Organisms isolated 
S.no Organism Number among positive cultures (n=13) Percentage 
1 Staphylococcus aureus 1 7.69 
2 Klebsiella 5 38.46 
3 Pseudomonas 5 38.46 
4 Coagulase negative staphylococcus aureus 1 7.69 
5 Diphtheroids 1 7.69 
Klebsiella 5(38.46%) and Pseudomonas 5(38.46%) were the most common organisms isolated (Table 3). 
Table 4: Drug prescription characteristics 
S. no Particulars Mean ± S.D. 
1 Average number of drugs prescribed per patient (including antibacterials) 10.25 ± 3.94 
2 Average number of drugs other than antibacterials prescribed per patient 7.1 ± 3.0 
3 Average number of antibacterials prescribed per patient 3.06 ± 1.67 
Table 5: Drugs other than antibacterials prescribed 
S. no Drug class Number of patients (n=52) Percentage 
1 Insulin 41 78.85 
2 Oral antidiabetic drugs 31 59.62 
3 Antiplatelets 12 23.08 
4 Statins 7 13.46 
5 Analgesics 40 76.92 
6 Drugs for treatment of peptic ulcer 43 82.69 
Anti-peptic ulcer agents [43(82.69%)], Insulin [41(78.85%)] and analgesics [40(76.92%)] were the most common 
drugs prescribed other than antibacterials. (Table V) 
Table 6: Agents prescribed for the management of diabetes mellitus 
S no Drug class Number(n=52) Percentage 
1 Insulin as one of the agents 41 78.85 
2 Oral antidiabetic drugs as one of the agents 31 59.62 
3 Both Insulin and Oral antidiabetic agents 20 38.46 
4 Insulin as the only agent 21 40.38 
5 Oral antidiabetic drugs as the only agent 11 21.15 
Insulin [41(78.85%)] was the most common antidiabetic agent used in the management of diabetes mellitus (Table 6). 
Antimicrobial data 
A total of 155 antibacterial agents were prescribed in 52 patients. Mean number of antibacterials prescribed per 
patient: 3.06 ± 1.67 Mean duration of antibacterial usage: 5.89 ± 3.48 days 
Table 7: Antibacterial prescription characteristics 
S.no Particulars Numbers(n=155) Percentage 
1 Single drug formulations 109 70.32 
2 Fixed dose combinations 46 29.68 
3 Drugs approved by DCGI 144 92.90 
4 Drugs approved by FDA 135 87.10 
5 Drugs prescribed listed in WHO essential drug list 101 65.16 
6 Drugs prescribed listed in national essential drug list 101 65.16 
7 Parenteral dosage forms prescribed (injectable) 97 62.58 
8 Tablet dosage forms prescribed 50 32.26 
9 Capsule dosage forms prescribed       8 5.16 
10 Oral route administered 58 37.42 
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11 I.V. route administered 97 62.58 
12 Drugs prescribed in generic name 16 10.32 
13 Drugs prescribed before C/S testing 125 80.65 
14 Drugs prescribed after C/S testing 30 19.35 
 
Out of the 155 antibacterials, single drug 
formulations were the most commonly prescribed 
[109 (70.32%)], 144 (92.9%) drugs were approved 
by DCGI and 135 (87.1%) by FDA. 101 (65.16%) 
drugs were included in both WHO and NLEM. 
Parenteral formulations were the commonly used 
dosage forms [97 (62.58%)]. Only 16 (10.32%) drugs 
were prescribed by their generic names. 125 
(80.65%) antibacterials were prescribed before and 
30 (19.35%) after culture sensitivity testing was done 
(table 7).Out of 52 patients, a total of 35 (67.31%) 
received FDC antibacterial drug formulations, 17 
(32.69%) received only single drug formulation 
antibacterials and 4(7.69%) received only FDCs; 
41(78.85%) received both injectable and oral 
formulations, 11(21.15%) received injectables only 
and 1(1.92%) received oral formulations only. 
Table 8: Single drug formulation antibacterials characteristics 
 
[ATC class: J01: Antibacterials for systemic use] 
S 
no 
Drug ATC code No (%) of 
prescriptions 
(n=109) 
DDD 
WHO 
DDD 
Calcul- 
ated 
Mean duration of 
antibacterials (days) 
prescribed ± 
S.D. 
ATC class: J01G; Drug class: Aminoglycoside antibacterials 
1 Inj Amikacin J01GB06 3(2.75) 1g 1g 4.33±1.15 
2 Inj Gentamicin J01GB03 1(0.92) 0.24g 0.16g 5 
ATC class: J01D; Drug class: Other beta – lactam antibacterials  
3 Inj Cefepime J01DE01 1(0.92) 2g 2g 6 
4 Tab Cefixime J01DD08 15(13.76) 0.4g 0.4g 8.67±5.69 
5 Inj Cefotaxime J01DD01 11(10.09) 4g 2g 5.97±2.51 
6 Tab Cefprozil J01DC10 1(0.92) 1g 1g 5 
7 Inj Ceftriaxone J01DD04 15(10.09) 2g 2g 4.80±1.70 
8 Tab cefuroxime J01DC02 5(4.59) 0.5g 0.9g 5.60±2.07 
9 Inj Meropenem J01DH02 1(0.92) 2g 3g 5 
ATC class: J01M; Drug class: Quinolone antibacterials 
10 Tab Ciprofloxacin J01MA02 3(2.75) 1g 1g 6±4.58 
11 Tab Gatifloxacin J01MA16 2(1.84) 0.4g 0.4g 5±1.41 
12 Tab Ofloxacin J01MA01 4(3.67) 0.4g 0.5g 7.5±2.38 
ATC class: J01F; Drug class: Macrolides, lincosamides & streptogramins 
13 Tab Clindamycin J01FF01 9(8.26) 1.2g 0.7g 4.22±2.54 
14 Cap Clindamycin J01FF01 8(7.34) 1.2g 0.9g 6.13±3.09 
15 Inj Clindamycin J01FF01 4(3.67) 1.8g 0.6g 6.25±2.50 
ATC class: J01X; Drug class: Other antibacterials 
16 Inj Linezolid J01XX08 8(7.34) 1.2g 0.9g 4.63±1.41 
17 Tab Linezolid J01XX08 3(2.75) 1.2g 0.6g 8 
18 Inj Metronidazole J01XD01 15(10.09) 1.5g 1.5g 6.13±3.91 
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ATC class: NA Drug class: NA 
19 Tab Satronidazole NA 1(0.92) NA 0.6g 8 
Table 9: Fixed dose combination antibacterials characteristics 
Sl no Drug ATC code No (%) of 
prescriptions 
(n=46) 
DDD 
WHO 
DDD 
Calcul- 
ated 
Mean duration of 
antibacterials 
(days) prescribed 
± S.D. 
ATC class: J01C; Drug class: Beta-lactam antibacterials, Penicillins 
1 Tab Amoxicillin+ 
Clavulanic acid 
J01CR02 4(8.70) 1g 1.56g 6±1.41 
2 Inj Amoxicillin 
+Clavulanic acid 
J01CR02 9(19.57) 3g 2.53g 4.44±2.51 
3 Inj Piperacillin + 
Tazobactam 
J01CR05 13(28.26) 14g 11.77g 5.15±2.38 
ATC class: J01D; Drug class: Other beta-lactam antibacterials 
4 Inj Cefoperazone+ 
Sulbactam 
J01DD62 7(15.21) 4g 3g 3.86±2.41 
5 Inj Ceftriaxone 
+Sulbactam 
J01DD54 6(13.04) NA 3g 4.67±2.73 
6 Inj Ceftriaxone + 
 Tazobactam 
J01DD54 2(4.35) NA 2.25g 5 
ATC class: NA; Drug class: NA 
7 Tab Ampicillin + 
Cloxacillin 
NA 1(2.17) NA 1.5g 6 
8 Tab Cefixime + 
Clavulanic acid 
NA 1(2.17) NA NA 5 
9 Inj Cefotaxime 
+Sulbactam 
NA 1(2.17) NA 3g 5 
10 Tab Cefpodoxime 
+ Potassium 
Clavulanate 
NA 1(2.17) NA 0.65g 3 
Table 10: Most common antibacterials prescribed 
S no Drug Number(n=155) Percentage 
1 Inj/Tab/Cap Clindamycin 21 13.55 
2 Tab Cefixime 15 9.68 
3 Inj Ceftriaxone 15 9.68 
4 Inj Metronidazole 15 9.68 
 
Of the 155 antibacterials, Inj/Tab/Cap Clindamycin [21(13.55%)], Tab cefixime, Inj Ceftriaxone and Inj 
Metronidazole were most commonly prescribed [15 (9.68%)]; (Table X). 
Table 11: Most common single drug formulation antibacterials prescribed 
S no Drug Number(n=109) Percentage 
1                   Inj/Tab/Cap Clindamycin 21 19.27 
2 Tab Cefixime 15 13.76 
3 Inj Ceftriaxone 15 13.76 
4 Inj Metronidazole 15 13.76 
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Of the 109 single drug formulation antibacterials, Inj/Tab/Cap Clindamycin [21(19.27%)], Tab Cefixime, Inj 
Ceftriaxone and Inj Metronidazole were most commonly prescribed [15 (13.76%) each] (Table 11). 
 
Table 12: Most Common FDC Antibacterials prescribed 
Sr.no Drug Number(n=46) Percentage 
1 Inj Piperacillin + Tazobactam 13 28.26 
2 Inj Amoxicillin + Clavulanic acid 9 19.57 
3 Inj Cefoperazone + Sulbactam 7 15.22 
Out of 46 FDC antibacterials prescribed, Inj Piperacillin + Tazobactam [13 (28.26%)] was the most common 
combination followed by Inj Amoxicillin + Clavulanic acid [9 (19.57%)] and Inj Cefoperazone + Sulbactam 
[7(15.22%)] {Table 12}. 
 
Table 13: Most common antibacterials used as empiric agent 
Sr. no Drug Number(n=125) Percentage 
1 Clindamycin 18 14.40 
2 Ceftriaxone 14 11.20 
3 Metronidazole 14 11.20 
4 Cefixime 12 9.60 
5                      Piperacillin + Tazobactam 12 9.60 
6               Amoxicillin + Clavulanic acid 11 8.80 
7 Cefotaxime 10 8.00 
 
 
Among 125 antibacterials prescribed as empiric agent i.e., before C/S testing, Clindamycin was the most preferred 
agent [18 (14.40%)] followed by both Ceftriaxone and Metronidazole [14 (11.20%)]. Beta-lactams comprised the 
major class of antibacterials prescribed before C/S testing [79(63.20%)]. 
Table 14: Most common antibacterials prescribed after C/S reports 
 
Sl  no Drug Number(n=30) Percentage 
1 Linezolid 4 13.33 
2 Clindamycin 3 10.00 
3              Cefoperazone + Sulbactam 3 10.00 
4 Cefixime 3 10.00 
5 Ofloxacin 3 10.00 
6          Amoxicillin + Clavulanic acid 2 6.67 
 
Among 30 antibacterials prescribed after C/S testing, Linezolid was the highest [4 (13.33%)] followed by 
Clindamycin, Cefoperazone + Sulbactam, Cefixime and Ofloxacin [3 (10%) each] [Table XXXXIII]. Beta-lactams 
comprised the major class of antibacterials prescribed after C/S testing [15(50%)]. 
Table 15: Number of antibacterials approved and listed in WHO / National List of Essential Medicines 
Drug formulation Approved by Listed in essential medicines list 
DCGI FDA WHO National 
Single drug(n=109) 106 (97.25 %) 108 (99.08 %) 87 (79.82 %) 87 (79.82 %) 
FDC (n=46) 38 (82.60 %) 27 (58.69 %) 14 (30.43 %) 14 (30.43 %) 
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Out of 46 FDCs, 38 (82.60%) and 27 (58.69%) drugs were approved by DCGI and FDA respectively and 14 
(30.83%) drugs were listed in both WHO essential medicines list and NLEM (Table 15). 
Table 16: Average cost of antibacterials prescribed 
S 
no 
Drug Average cost of single dose 
of antibacterial in Rs. 
(Mean ±S.D.) 
Average cost of 
antibacterials 
prescribed during 
hospital stay in Rs. 
(Mean ±S.D.) 
Average Cost 
per calculated 
DDD in Rs. 
(Mean ±S.D.) 
1 Inj Amikacin 69.92 ± 9.83 497.63 ± 76.27 139.85 ± 19.66 
2 Inj Gentamicin 8.9 89 17.8 
3 Inj Cefepime 190 2280 380 
4 Tab Cefixime 19.16 ± 2.10 330.16 ± 210.68 38.32 ± 4.20 
5 Inj Cefotaxime 30.99 366.25 ± 155.46 61.98 
6 Tab Cefprozil 55 550 110 
7 Inj Ceftriaxone 118.28 ± 19.98 1175.44 ± 464.11 236.56 ± 39.97 
8 Tab Cefuroxime 76.28 ± 20.34 792.49 ± 147.54 152.56 ± 40.67 
9 Inj Meropenem 2450 36750 7350 
10 Tab Ciprofloxacin 8.3 ± 1.68 109.3 ± 88.14 16.6 ± 3.36 
11 Tab Gatifloxacin 9.6 ± 3.39 45.6 ± 3.39 9.6 ± 3.39 
12 Tab Ofloxacin 5.26 ± 1.27 104.37 ± 48.94 10.51 ± 2.55 
13 Tab Clindamycin 37.78 ± 4.87 397.56 ± 293.30 93.07 ± 25.57 
14 Cap Clindamycin 59.10 ± 21.06 704.28 ± 229.20 118.20 ± 42.12 
15 Inj Clindamycin 84 1050 ± 420 168 
16 Inj Linezolid 235.63 ± 75.04 1957.50 ± 952.41 435.00 ± 155.01 
17 Tab Linezolid 49.38 790 98.75 
 
Table 17: Average cost of injectable and oral formulations of antibacterials prescribed 
Formulation Mean duration 
prescribed (days) 
Average cost of single 
dose of the 
formulation in Rs. 
Average cost of the 
formulation 
prescribed during 
hospital stay in Rs. 
Injectable 5.44 ± 3.13 215.28 2625.69 
Oral 6.71 ± 3.95 33.92 431.33 
Injectables were prescribed for a mean duration of 
5.44 ± 3.13days and oral formulations for 6.71 ± 3.95 
days. Average cost of single dose and that prescribed 
during hospital stay was Rs. 215.28 and Rs. 2625.69 
for injectables and Rs. 33.92 and Rs.431.33 for oral 
formulations respectively. 
 
Discussion 
Antimicrobial agents are commonly employed in the 
management of diabetic foot ulcers, the most 
important and widely prescribed being antibacterial 
agents. All cases of diabetic foot ulcers with clinical 
evidence of infection must be treated with 
antibacterial agents. Empiric antibacterials are 
usually started based on previous experiences of 
clinicians and are narrowed down to definitive 
antibacterial therapy after culture and sensitivity 
reports have been obtained.16 In the present study, the 
prescribing patterns of antibacterial agents and other 
drugs used concurrently in the management of DFUs 
have been studied. Also, an attempt has been made to 
analyse the cost of antibacterials used in the present 
study.The data of 52 patients admitted with a 
diagnosis of DFUs during the period XXXXX were 
analysed. In the present study, the prevalence of DFU 
was more in males [47 (90%)] than females [5(10%)] 
{fig.4}, which is similar to a study done by 
Bengalorkar GM et al[17]. The mean age of males 
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was 56.02 ± 11.95 years and that of females 65.6 ± 
15.19 years. Patients aged between 51-60 years were 
the most affected  [16 (30.77%)] .Hypertension 
[20(38%)] was the most common co-morbid illness 
followed by nephropathy [3(6%)] and 
cerebrovascular accidents [2(4%)] {fig.6}. The mean 
duration of hospital stay was 22.81 ± 18.57 days.The 
most common surgical intervention was debridement 
[33(63%)], followed by skin grafting [5(9.6%)] and 
only 11(21.15%) patients had undergone more than 
one surgical intervention.Unlike reports from western 
countries[18], the most common organisms isolated 
in the present study were gram negative in nature 
which included Klebsiella [5(38.46%)] and 
Pseudomonas species [5(38.46%)]. This is 
comparable to the results obtained by Bengalorkar 
GM et al.,.6 The gram positive organisms isolated 
were Staphylococcus aureus, Coagulase negative 
staphylococcus aureus and Diphtheroids [1(7.69%) 
each] {Table XXXII, fig.10, 12}. The increased 
prevalence of gram negative bacilli in DFU patients 
could be attributed to unhygienic sanitary 
habits[8].The average number of overall drugs 
prescribed per patient was 10.25 ± 3.94.Excluding 
antibacterials, the average number of drugs 
prescribed was 7.1 ± 3.0.Excluding antibacterials, 
drugs for peptic ulcer [43(82.69%)] were the most 
commonly prescribed preparations, followed by 
insulin [41 (78.85%)] and analgesics [40 (76.92%)] . 
Insulin [41 (78.85%)] was the most common 
antidiabetic agent prescribed for the management of 
DM.The average number of antibacterials prescribed 
per patient was 3.06 ± 1.67. The mean duration for 
which antibacterials were prescribed was 5.89 ± 3.48 
days. A total of 155 antibacterials were prescribed in 
52 patients, of which 109(70.32%) were single drug 
antibacterial formulations, 46 (29.68%) were fixed 
dose combinations. 144 (92.90%) and 135 (87.10%) 
antibacterials were approved by DCGI and USFDA 
respectively. More than half of antibacterials [101 
(65.16%)] used in the management of DFU were 
listed in both WHO essential medicines list and 
NLEM. Among the prescribed antibacterials, 2/3rd 
were injectables [97(62.58%)] and 1/3rd oral 
formulations 58(37.42%). Around 10% [16(10.32%)] 
of antibacterials were prescribed by their generic 
names. A total of 125(80.65%) and 30(19.35%) 
antibacterials were prescribed before and after C/S 
testing respectively.Out of 52 patients, a total of 35 
(67.31%) received FDC antibacterial drug 
formulations, 17 (32.69%) received only single drug 
formulation antibacterials and 4(7.69%) received 
only FDCs; 41(78.85%) received both injectable and 
oral formulations, 11(21.15%) received injectables 
only and 1(1.92%) received oral formulations only. 
The most common antibacterials prescribed were 
Clindamycin [21(13.55%)], Cefixime 200mg BD, 
Ceftriaxone 1g BD and Metronidazole 500mg TID, 
[15(9.68%) each]. The most common injectables 
used were Inj. Ceftriaxone and Inj. Metronidazole 
[15(15.46%) each]; Tab/Cap Clindamycin 
[17(29.31%)] and Tab Cefixime [15(25.86%)] were 
the most common oral formulations used. The most 
common single drug formulations prescribed were 
Clindamycin [21(19.27%)], Cefixime 200mg BD, 
Ceftriaxone 1g BD and Metronidazole 500mg TID, 
[15(13.76%) each] {Table XXXX}. The most 
common FDC antibacterials prescribed were Inj. 
Piperacillin + Tazobactam 4.5g [13(28.26%)] 
followed by Inj. Amoxicillin + Clavulanic acid 1.2g 
[9(19.57%)] and Inj. Cefoperazone + Sulbactam 
1.5g [7(15.22%.)].The most common class of 
antibacterials prescribed was beta-lactams (ATC 
class: J01D and J01C) [90(58.07%)]. Among the 155 
antibacterials, 125(80.65%) were prescribed 
empirically and 30(19.35%) after C/S testing. Beta-
lactams comprised the major class of antibacterials 
prescribed before and after C/S testing [79(63.2%) 
and 15(50%) respectively]. Beta-lactam antibacterials 
have wider gram negative coverage[19].Irrespective 
of C/S testing, majority of prescriptions in the present 
study were that of beta-lactam antibacterials. Since, 
C/S testing yielded more gram negative isolates, the 
prescription of above antibacterials is justified.The 
antibacterials which were not approved by DCGI 
include Gatifloxacin, Satronidazole, FDC of 
Ampicillin and Cloxacillin, Cefoperazone and 
Sulbactam; those not approved by FDA include 
Satronidazole, Ampicillin + Cloxacillin, Cefixime + 
Clavulanic acid, Cefoperazone + Sulbactam, 
Cefotaxime + Sulbactam, Cefpodoxime + Potassium 
Clavulanate, Ceftriaxone + Sulbactam and 
Ceftriaxone + Tazobactam. The antibacterials which 
were not approved by any of the regulatory bodies 
include Satronidazole, FDC of Ampicillin and 
Cloxacillin, Cefoperazone and Sulbactam.The 
antibacterials Cefepime, Cefprozil, Cefuroxime, 
Gatifloxacin, Linezolid, Meropenem, Satronidazole 
and all the FDCs except Amoxicillin + Clavulanic 
acid were not enlisted in the WHO essential 
medicines list and NLEM. Taking into consideration, 
the approval status, cost and the frequency in which 
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the antibacterials were prescribed, the following 
drugs could be suggested to be included in the 
essential medicines list: Cefuroxime, Linezolid and 
Ceftriaxone + Sulbactam. Even though the cost of 
Piperacillin+ Tazobactam was very high (Rs. 681.91 
± 166.21), it was commonly prescribed. Hence, 
Piperacillin + Tazobactam preparations could be 
suggested for inclusion in the essential medicines list 
and as well be made available at reasonable 
rates.More than 97% of single drug formulations 
were approved by DCGI and FDA and 80% were 
enlisted in both WHO and NLEM. In comparison, the 
number of FDCs approved by DCGI and FDA were 
38(82.60%) and 27(58.69%) respectively and only 
30.43% were listed in both WHO and NLEM. These 
statistics suggest that most of the FDCs prescribed 
were not listed in Essential medicines 
list.Considering only the approved preparations, Inj. 
Meropenem (Rs. 2450) was the most expensive drug 
prescribed and Tab. Ofloxacin (Rs. 5.26) was the 
least. The total cost of antibacterial for the total 
duration of stay was least for Inj. Gentamicin (Rs. 
89) followed by Tab. Ofloxacin (Rs.104.37) and it 
was the most expensive for Inj. Meropenem 
(Rs.36750) followed by Inj. Piperacillin + 
Tazobactam (Rs. 9591.15). The average cost per 
calculated DDD was least for Tab. Ofloxacin [Rs. 
10.51 ± 2.55] and highest for Inj. Meropenem [Rs. 
7350]. Taking the drug class into account, the cost 
per dose and the total cost during hospital stay was 
least for quinolones [Rs. 7.24 and Rs.92.95 
respectively], and most expensive for β-Lactam 
antibacterials [Rs. 416.97 and Rs.5539.06 
respectively].Quinolones have a wide range of 
coverage against organisms[19].These organisms 
include the ones isolated in the present study as well 
as other studies done in India by Umadevi S et 
al.[6]Ramakant P et al.[8] Bengalorkar GM et al.[17] 
and Gadepalli R et al[20]. As quinolones have wide 
antibiotic coverage and are cost effective, they could 
be preferred as an empiric agent in the management 
of DFUs keeping in mind their resistance  patterns. 
 
Conclusion 
Gram negative organisms were the most common 
organisms isolated.Parenteral formulations were 
preferred over oral in the management of DFUs. Single 
drug formulations were preferred over FDCs in the 
management of DFUs. Beta-lactams comprised the 
major class of antibacterials prescribed before and after 
C/S testing. More than 80% of the antibacterials 
prescribed were approved by USFDA and DCGI. 
Almost 60% of the antibacterials prescribed were 
included in the WHO essential medicines list and 
National List of Essential Medicines. The average cost 
per dose and the total cost during hospital stay were 
highest for β- lactam antibacterials and least for 
quinolones. 
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